Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia

Zhou,Hao; Zhou,Hao; Zhang,Qing; Zhang,Qing; Huang,Wei; Huang,Wei; He,Chunping; He,Chunping; Zhou,Chang; Zhou,Chang; Zhou,Jianlin; Zhou,Jianlin; Ning,Yichong; Ning,Yichong

doi:10.3892/ijo.2023.5512

Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia

Authors:
- Hao Zhou
- Qing Zhang
- Wei Huang
- Chunping He
- Chang Zhou
- Jianlin Zhou
- Yichong Ning
View Affiliations

Affiliations: State Key Laboratory of Developmental Biology of Freshwater Fish & Key Laboratory of Protein Chemistry and Developmental Biology of the Ministry of Education, College of Life Science, Hunan Normal University, Changsha, Hunan 410081, P.R. China, Chongzuo Key Laboratory of Biomedical Clinical Transformation, The People's Hospital of Chongzuo, Youjiang Medical University for Nationalities, Chongzuo, Guangxi Zhuang Autonomous Region 532200, P.R. China
Published online on: April 13, 2023 https://doi.org/10.3892/ijo.2023.5512
Article Number: 64
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gene encoding the tumor suppressor p53 is the most frequently mutated gene in cancers. However, p53 mutation is rare in acute myeloid leukemia (AML), and p53 is inactivated predominantly by aberrant expression of p53 regulators (such as MDM2). A previous study by the authors revealed that the ZCCHC10 protein suppressed MDM2‑mediated degradation of the p53 protein in lung cancer. However, the expression and role of the ZCCHC10 gene in AML have not been investigated. In the present study, it was found that ZCCHC10 expression was downregulated in bone marrow samples of AML patients and that ZCCHC10 expression was significantly and negatively correlated with the expression of the lncRNA SNHG1. Suppression of SNHG1 decreased ZCCHC10 promoter methylation and increased ZCCHC10 expression. Notably, there is a putative binding motif in SNHG1 with full complementarity to five sites surrounding the CpG island in the ZCCHC10 promoter. Overexpression of wild‑type SNHG1 promoted ZCCHC10 methylation, but overexpression of SNHG1 with deletion of the binding motif did not. Further study identified that SNHG1 simultaneously bound to the ZCCHC10 promoter and the DNA methyltransferases DNMT1 and DNMT3B. These results indicated that SNHG1 recruits DNMT1 and DNMT3B to the ZCCHC10 promoter, resulting in hypermethylation of the ZCCHC10 promoter. Kaplan‑Meier survival analysis showed that ZCCHC10 expression was positively associated with overall survival in AML patients. In vitro experiments demonstrated that ZCCHC10 increased p53 expression and suppressed AML cell proliferation and survival. In the xenograft mouse model, ZCCHC10 decreased the proliferation of leukemic cells, improved the survival of leukemic mice, and increased sensitivity to the BCL inhibitor venetoclax. In conclusion, ZCCHC10 expression is suppressed by SNHG1‑induced DNA methylation in AML. Downregulation of ZCCHC10 decreases p53 activation, promotes cell proliferation and survival, and thereby accelerates AML progression and the acquisition of venetoclax resistance. The present study identified a SNHG1/ZCCHC10/p53 signaling axis in AML that may be a therapeutic target in this malignancy.

View Figures

View References

1	Chakraborty S and Park CY: Pathogenic mechanisms in acute myeloid leukemia. Curr Treat Options Oncol. 23:1522–1534. 2022. View Article : Google Scholar : PubMed/NCBI
2	Shallis RM, Wang R, Davidoff A, Ma X and Zeidan AM: Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 36:70–87. 2019. View Article : Google Scholar : PubMed/NCBI
3	Boutelle AM and Attardi LD: p53 and tumor suppression: It takes a network. Trends Cell Biol. 31:298–310. 2021. View Article : Google Scholar : PubMed/NCBI
4	Wen XM, Xu ZJ, Jin Y, Xia PH, Ma JC, Qian W, Lin J and Qian J: Association analyses of TP53 mutation with prognosis, tumor mutational burden, and immunological features in acute myeloid leukemia. Front Immunol. 12:7175272021. View Article : Google Scholar : PubMed/NCBI
5	Abramowitz J, Neuman T, Perlman R and Ben-Yehuda D: Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal acute myeloid leukemia and acute promyelocytic leukemia. BMC Med Genomics. 10:182017. View Article : Google Scholar : PubMed/NCBI
6	Quintas-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, Zhang N, Coombes K and Kornblau SM: p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status. Leukemia. 31:1296–1305. 2017. View Article : Google Scholar
7	Chen Q, Deng S, Deng M, Shi Y, Zhong M, Ding L, Jiang Y, Zhou Y, Carter BZ and Xu B: Therapeutic synergy of triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways. Exp Hematol Oncol. 11:232022. View Article : Google Scholar : PubMed/NCBI
8	Fang DD, Tang Q, Kong Y, Rong T, Wang Q, Li N, Fang X, Gu J, Xiong D, Yin Y, et al: MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 7:902021. View Article : Google Scholar : PubMed/NCBI
9	Pan R, Ruvolo V, Mu H, Leverson JD, Nichols G, Reed JC, Konopleva M and Andreeff M: Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: Mechanisms and superior antileukemic efficacy. Cancer Cell. 32:748–760.e6. 2017. View Article : Google Scholar : PubMed/NCBI
10	Ning Y, Hui N, Qing B, Zhuo Y, Sun W, Du Y, Liu S, Liu K and Zhou J: ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation. Cell Death Dis. 10:4142019. View Article : Google Scholar : PubMed/NCBI
11	Le Beau MM, Espinosa R III, Neuman WL, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M and Westbrook CA: Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci USA. 90:5484–5488. 1993. View Article : Google Scholar : PubMed/NCBI
12	Treppendahl MB, Qiu X, Søgaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Möllgård L, Hellström-Lindberg E, et al: Allelic methylation levels of the noncoding VTRNA21 located on chromosome 5q31.1 predict outcome in AML. Blood. 119:206–216. 2012. View Article : Google Scholar :
13	Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, Estey E, Kantarjian H, Garcia-Manero G and Issa JP: RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 67:1997–2005. 2007. View Article : Google Scholar : PubMed/NCBI
14	Bake V, Roesler S, Eckhardt I, Belz K and Fulda S: Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells. Cancer Lett. 355:224–231. 2014. View Article : Google Scholar : PubMed/NCBI
15	Peña-Martinez P, Eriksson M, Ramakrishnan R, Chapellier M, Högberg C, Orsmark-Pietras C, Richter J, Andersson A, Fioretos T and Järås M: Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6-dependent manner. Leukemia. 32:588–596. 2018. View Article : Google Scholar :
16	Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, et al: Functional genomic landscape of acute myeloid leukaemia. Nature. 562:526–531. 2018. View Article : Google Scholar : PubMed/NCBI
17	Chuang MK, Chiu YC, Chou WC, Hou HA, Tseng MH, Kuo YY, Chen Y, Chuang EY and Tien HF: An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. Oncotarget. 6:39098–39110. 2015. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Sun Y, Wei G, Luo H, Wu W, Skogerbø G, Luo J and Chen R: The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes. Oncogene. 36:6774–6783. 2017. View Article : Google Scholar : PubMed/NCBI
20	Liu X, Chen Q, Tsai HJ, Wang G, Hong X, Zhou Y, Zhang C, Liu C, Liu R, Wang H, et al: Maternal preconception body mass index and offspring cord blood DNA methylation: Exploration of early life origins of disease. Environ Mol Mutagen. 55:223–230. 2014. View Article : Google Scholar
21	Bao XL, Zhang L and Song WP: LncRNA SNHG1 overexpression regulates the proliferation of acute myeloid leukemia cells through miR-488-5p/NUP205 axis. Eur Rev Med Pharmacol Sci. 23:5896–5903. 2019.PubMed/NCBI
22	Tian M, Gong W and Guo J: Long non-coding RNA SNHG1 indicates poor prognosis and facilitates disease progression in acute myeloid leukemia. Biol Open. 8:bio0464172019. View Article : Google Scholar : PubMed/NCBI
23	Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, Xu T, Hu X, Sun L, et al: The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 17:1412018. View Article : Google Scholar : PubMed/NCBI
24	Wong KK, Lawrie CH and Green TM: Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid leukaemia. Biomarker Insights. 14:11772719198464542019. View Article : Google Scholar : PubMed/NCBI
25	Wei Y, Cao Y, Sun R, Cheng L, Xiong X, Jin X, He X, Lu W and Zhao M: Targeting Bcl-2 proteins in acute myeloid leukemia. Front Oncol. 10:5849742020. View Article : Google Scholar : PubMed/NCBI
26	Short NJ, Dombret H, Adès L and Kantarjian H: The evolution of research and therapy with hypomethylating agents in acute myeloid leukemia and myelodysplastic syndrome: New directions for old drugs. Cancer J. 28:29–36. 2022. View Article : Google Scholar : PubMed/NCBI
27	Stomper J, Rotondo JC, Greve G and Lubbert M: Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies. Leukemia. 35:1873–1889. 2021. View Article : Google Scholar : PubMed/NCBI
28	Thin KZ, Tu JC and Raveendran S: Long non-coding SNHG1 in cancer. Clin Chim Acta. 494:38–47. 2019. View Article : Google Scholar : PubMed/NCBI
29	Li C, Gao Q, Wang M and Xin H: LncRNA SNHG1 contributes to the regulation of acute myeloid leukemia cell growth by modulating miR-489-3p/SOX12/Wnt/β-catenin signaling. J Cell Physiol. 236:653–663. 2020. View Article : Google Scholar
30	Vaddavalli PL and Schumacher B: The p53 network: Cellular and systemic DNA damage responses in cancer and aging. Trends Genet. 38:598–612. 2022. View Article : Google Scholar : PubMed/NCBI
31	Ohira T, Kojima H, Kuroda Y, Aoki S, Inaoka D, Osaki M, Wanibuchi H, Okada F, Oshimura M and Kugoh H: PITX1 protein interacts with ZCCHC10 to regulate hTERT mRNA transcription. PLoS One. 14:e02176052019. View Article : Google Scholar : PubMed/NCBI
32	Ma ZH, Shi PD and Wan BS: MiR-410-3p activates the NF-κB pathway by targeting ZCCHC10 to promote migration, invasion and EMT of colorectal cancer. Cytokine. 140:1554332021. View Article : Google Scholar
33	Lehmann C, Friess T, Birzele F, Kiialainen A and Dangl M: Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. J Hematol Oncol. 9:502016. View Article : Google Scholar : PubMed/NCBI